Tilpotide is more effective than semeglutide for weight loss, and when GIP is used in combination with GLP-1 receptor agonists, it may have a greater effect on patients' blood sugar and body weight.
Competition on the diet pills circuit is becoming more intense, and Eli Lilly Mu Fengda has been approved for listing in China.
On May 21, the official website of the State Drug Administration revealed that Eli Mu Fengda (terpotide injection) was approved by the National Drug Administration (NMPA) to improve blood sugar control in adult type 2 diabetics.
Tilpotide is a weekly injectable GIPR and GLP-1R agonist. GLP-1 and GIP are two types of natural intestinal insulin. Studies have shown that GIP can reduce food intake and increase energy consumption, thereby reducing weight. When GIP is used in combination with GLP-1 receptor agonists, it may have a greater effect on patients' blood sugar and body weight.
It is worth mentioning that tirpotide can produce better weight loss results than simeglutide, known as the “magic drug for weight loss.”
Relevant research data showed that subjects with Mu Fengda 5 mg and 10 mg lost an average weight of 7.8 kg and 10.3 kg, while the smeglutide 1 mg group lost an average of 6.2 kg.
Last year, tirpotide was approved by the FDA for chronic weight management and weight-related complications such as high blood pressure, dyslipidemia, type 2 diabetes, obstructive sleep apnea, or cardiovascular disease. The trade name is Zepbound. Currently, the marketing application for titerpotide weight loss indications has also been accepted by the Drug Administration and is under review.
In addition, diet drug sales have also significantly boosted Lilai's performance. Zepbound's sales in the first quarter of its launch exceeded expectations, contributing 517 million US dollars in sales for the full quarter, exceeding analysts' expectations of 418 million US dollars. The company also raised its full-year revenue guidance by $2 billion.
Earlier, some industry analysts predicted that tilpotide may become one of the best-selling drugs in history, with annual sales exceeding 50 billion US dollars, surpassing Novo Nordisk's smeglutide drugs Ozempic and Wegovy.
Currently, Eli Lilly's market capitalization has reached 744.3 billion US dollars, higher than Tesla and Walmart in the S&P constituent stocks, and is the pharmaceutical company with the highest market capitalization in the world.